Cargando…
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults
We evaluated the immunogenicity and reactogenicity of heterologous COVID-19 primary schedules involving BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCoV-19 (AstraZeneca) and CoronaVac (Sinovac) in healthy adults, as well as booster response to BNT162b2 following heterologous CoronaVac and ChAdOx1 nCoV-19 re...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746495/ https://www.ncbi.nlm.nih.gov/pubmed/35816053 http://dx.doi.org/10.1080/21645515.2022.2091865 |
_version_ | 1784849374342283264 |
---|---|
author | Niyomnaitham, Suvimol Quan Toh, Zheng Wongprompitak, Patimaporn Jansarikit, Laddawan Srisutthisamphan, Kanjana Sapsutthipas, Sompong Jantraphakorn, Yuparat Mingngamsup, Natthakarn Licciardi, Paul V Chokephaibulkit, Kulkanya |
author_facet | Niyomnaitham, Suvimol Quan Toh, Zheng Wongprompitak, Patimaporn Jansarikit, Laddawan Srisutthisamphan, Kanjana Sapsutthipas, Sompong Jantraphakorn, Yuparat Mingngamsup, Natthakarn Licciardi, Paul V Chokephaibulkit, Kulkanya |
author_sort | Niyomnaitham, Suvimol |
collection | PubMed |
description | We evaluated the immunogenicity and reactogenicity of heterologous COVID-19 primary schedules involving BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCoV-19 (AstraZeneca) and CoronaVac (Sinovac) in healthy adults, as well as booster response to BNT162b2 following heterologous CoronaVac and ChAdOx1 nCoV-19 regimens. Participants were randomized to one of seven groups that received two-dose homologous BNT162b2 or heterologous combinations of CoronaVac, ChAdOx1 nCoV-19 and BNT162b2, with 4 weeks interval. A total of 210 participants were enrolled, 30 in each group. Median age of participants was 38 (19–60) years, and 108/210 (51.43%) were female. Overall adverse events after the second dose were mild to moderate. We found that groups that received BNT162b2 as second dose induced the highest anti-receptor binding domain IgG response against the ancestral strain [BNT162b2: geometric mean concentration (GMC) 2133–2249 BAU/mL; ChAdOx1 nCoV-19: 851–1201; CoronaVac: 137–225 BAU/mL], neutralizing antibodies (NAb) against Beta and Delta, and interferon gamma response. All groups induced low to negligible NAb against Omicron after second dose. A BNT162b2 booster (third dose) following heterologous CoronaVac and ChAdOx1 nCoV-19 regimens induced >140-fold increase in NAb titers against Omicron. Our findings indicate that heterologous regimens using BNT162b2 as the second dose may be an alternative schedule to maximize immune response. While heterologous two-dose schedules induced low NAb against Omicron, the use of an mRNA vaccine booster dose substantially increased the Omicron response. These findings are relevant for low-income countries considering heterologous primary and booster COVID-19 vaccine schedules. |
format | Online Article Text |
id | pubmed-9746495 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-97464952022-12-14 Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults Niyomnaitham, Suvimol Quan Toh, Zheng Wongprompitak, Patimaporn Jansarikit, Laddawan Srisutthisamphan, Kanjana Sapsutthipas, Sompong Jantraphakorn, Yuparat Mingngamsup, Natthakarn Licciardi, Paul V Chokephaibulkit, Kulkanya Hum Vaccin Immunother Coronavirus – Research Paper We evaluated the immunogenicity and reactogenicity of heterologous COVID-19 primary schedules involving BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCoV-19 (AstraZeneca) and CoronaVac (Sinovac) in healthy adults, as well as booster response to BNT162b2 following heterologous CoronaVac and ChAdOx1 nCoV-19 regimens. Participants were randomized to one of seven groups that received two-dose homologous BNT162b2 or heterologous combinations of CoronaVac, ChAdOx1 nCoV-19 and BNT162b2, with 4 weeks interval. A total of 210 participants were enrolled, 30 in each group. Median age of participants was 38 (19–60) years, and 108/210 (51.43%) were female. Overall adverse events after the second dose were mild to moderate. We found that groups that received BNT162b2 as second dose induced the highest anti-receptor binding domain IgG response against the ancestral strain [BNT162b2: geometric mean concentration (GMC) 2133–2249 BAU/mL; ChAdOx1 nCoV-19: 851–1201; CoronaVac: 137–225 BAU/mL], neutralizing antibodies (NAb) against Beta and Delta, and interferon gamma response. All groups induced low to negligible NAb against Omicron after second dose. A BNT162b2 booster (third dose) following heterologous CoronaVac and ChAdOx1 nCoV-19 regimens induced >140-fold increase in NAb titers against Omicron. Our findings indicate that heterologous regimens using BNT162b2 as the second dose may be an alternative schedule to maximize immune response. While heterologous two-dose schedules induced low NAb against Omicron, the use of an mRNA vaccine booster dose substantially increased the Omicron response. These findings are relevant for low-income countries considering heterologous primary and booster COVID-19 vaccine schedules. Taylor & Francis 2022-07-11 /pmc/articles/PMC9746495/ /pubmed/35816053 http://dx.doi.org/10.1080/21645515.2022.2091865 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Coronavirus – Research Paper Niyomnaitham, Suvimol Quan Toh, Zheng Wongprompitak, Patimaporn Jansarikit, Laddawan Srisutthisamphan, Kanjana Sapsutthipas, Sompong Jantraphakorn, Yuparat Mingngamsup, Natthakarn Licciardi, Paul V Chokephaibulkit, Kulkanya Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults |
title | Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults |
title_full | Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults |
title_fullStr | Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults |
title_full_unstemmed | Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults |
title_short | Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults |
title_sort | immunogenicity and reactogenicity against the sars-cov-2 variants following heterologous primary series involving coronavac, chadox1 ncov-19 and bnt162b2 plus bnt162b2 booster vaccination: an open-label randomized study in healthy thai adults |
topic | Coronavirus – Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746495/ https://www.ncbi.nlm.nih.gov/pubmed/35816053 http://dx.doi.org/10.1080/21645515.2022.2091865 |
work_keys_str_mv | AT niyomnaithamsuvimol immunogenicityandreactogenicityagainstthesarscov2variantsfollowingheterologousprimaryseriesinvolvingcoronavacchadox1ncov19andbnt162b2plusbnt162b2boostervaccinationanopenlabelrandomizedstudyinhealthythaiadults AT quantohzheng immunogenicityandreactogenicityagainstthesarscov2variantsfollowingheterologousprimaryseriesinvolvingcoronavacchadox1ncov19andbnt162b2plusbnt162b2boostervaccinationanopenlabelrandomizedstudyinhealthythaiadults AT wongprompitakpatimaporn immunogenicityandreactogenicityagainstthesarscov2variantsfollowingheterologousprimaryseriesinvolvingcoronavacchadox1ncov19andbnt162b2plusbnt162b2boostervaccinationanopenlabelrandomizedstudyinhealthythaiadults AT jansarikitladdawan immunogenicityandreactogenicityagainstthesarscov2variantsfollowingheterologousprimaryseriesinvolvingcoronavacchadox1ncov19andbnt162b2plusbnt162b2boostervaccinationanopenlabelrandomizedstudyinhealthythaiadults AT srisutthisamphankanjana immunogenicityandreactogenicityagainstthesarscov2variantsfollowingheterologousprimaryseriesinvolvingcoronavacchadox1ncov19andbnt162b2plusbnt162b2boostervaccinationanopenlabelrandomizedstudyinhealthythaiadults AT sapsutthipassompong immunogenicityandreactogenicityagainstthesarscov2variantsfollowingheterologousprimaryseriesinvolvingcoronavacchadox1ncov19andbnt162b2plusbnt162b2boostervaccinationanopenlabelrandomizedstudyinhealthythaiadults AT jantraphakornyuparat immunogenicityandreactogenicityagainstthesarscov2variantsfollowingheterologousprimaryseriesinvolvingcoronavacchadox1ncov19andbnt162b2plusbnt162b2boostervaccinationanopenlabelrandomizedstudyinhealthythaiadults AT mingngamsupnatthakarn immunogenicityandreactogenicityagainstthesarscov2variantsfollowingheterologousprimaryseriesinvolvingcoronavacchadox1ncov19andbnt162b2plusbnt162b2boostervaccinationanopenlabelrandomizedstudyinhealthythaiadults AT licciardipaulv immunogenicityandreactogenicityagainstthesarscov2variantsfollowingheterologousprimaryseriesinvolvingcoronavacchadox1ncov19andbnt162b2plusbnt162b2boostervaccinationanopenlabelrandomizedstudyinhealthythaiadults AT chokephaibulkitkulkanya immunogenicityandreactogenicityagainstthesarscov2variantsfollowingheterologousprimaryseriesinvolvingcoronavacchadox1ncov19andbnt162b2plusbnt162b2boostervaccinationanopenlabelrandomizedstudyinhealthythaiadults |